Home | Publications | Regulation & Policy | Intellectual Property place holder
place holder place holder

Intellectual Property

Pharmaceutical Anti-Counterfeiting Strategies

Protecting profits through operational security, new technologies and industry partnerships

Publication Date   January 2005
Publisher   Business Insights
Product Type   Report
Pages   117
ISBN Number   not applicable
Product Code   RBI039
Ask a question about this product?

Price £1,495.00

approximately: $2,640 | €1,896

Summary


The counterfeiting of pharmaceutical products is a multi-billion dollar industry and pharmaceutical companies must take measures to protect their products and profits: counterfeiting was previously a problem limited to developing countries, but in recent years with the increase in parallel trading and Internet pharmacies, the industry has also thrived in industrialized nations such as the US and in the EU. Pharmaceutical Anti-Counterfeiting Strategies: Protecting profits through operational security, new technologies and industry partnerships, is a new report which provides a detailed analysis of actionable product protection strategies drawing heavily from case studies and a survey of industry leaders. Unlike other reports on counterfeit drugs that only tackle the issue of anti-counterfeiting technology, this report also covers essential strategies involving internal organization, supply chain management, and cooperation with national and international agencies, giving you a complete guide to a full anti-counterfeiting strategy.

Content


  • Executive Summary
    • The Scale Of Drug Counterfeiting
    • Secure Business Practices
    • Security Technology Strategies
    • Cooperation With National & International Agencies
  • Chapter 1 The Scale Of Drug Counterfeiting
    • Summary
    • Introduction
    • Defining Counterfeit Drugs
    • Fake Drugs
    • Fake Labels
    • Scale And Economic Cost Of Counterfeiting
    • Estimates Of Counterfeiting
    • Global
    • Developed Countries
    • Developing Countries
    • Increase In Counterfeiting
    • Health Cost Of Counterfeiting
    • Asia
    • South America
    • Africa
    • Drugs At Risk Of Counterfeiting
    • Current Assessment
    • Industrialized Nations
    • Developing Countries
    • Future Assessment
    • Drivers And Enablers Of Counterfeiting
    • Mechanism Of Counterfeiting
    • Us
    • Eu
    • Internet Pharmacies And Spam Email
    • Anti-Counterfeiting Strategies
  • Chapter 2 Secure Business Practices
    • Summary
    • Introduction
    • Risk Assessment
    • Current Trends In Anti-Counterfeiting Company Organization
    • Setting Up An Anti-Counterfeiting Project Team
    • Overall Responsibilities
    • Individual Function Responsibilities
    • Legal
    • Regulatory
    • Supply Chain Management And Security
    • Product Development
    • Production And Packaging Design
    • Sales And Marketing
    • Public Relations
    • Finance
    • Supply And Distribution Control
    • Case Study: Johnson & Johnson Introduces New Contracts For
    • Distributors
    • Responding To Reports Of Counterfeiting
    • Case Study: Pfizer Legal Action And Consumer Education
    • Illegal Online Pharmacies
    • Patient Education
  • Chapter 3 Security Technology Strategies
    • Summary
    • Introduction
    • Anti-Counterfeiting Technologies
    • Preventative Technologies
    • Unit-Of-Use Packaging
    • Tamper-Evident Packaging
    • Authentication Technologies
    • Overt Technologies
    • Covert Technologies
    • Forensic Technologies
    • Cost To Manufacturers
    • Cost To Wholesalers And Retailers
    • Track & Trace Technologies
    • Barcodes
    • Radio Frequency Identification Technology
    • Epc
    • Rfid
    • Rfid And Unit-Of-Use Packaging
    • Should You Adopt Rfid Now?
    • Companies Required To Comply
    • Companies Not Required To Comply
    • Drugs For Developing Countries
    • Rfid Roi Example Analysis
    • Industry-Wide Pilot Rfid Project
    • Tracking Throughout The Supply Chain
    • Case Study: Csv Corp's Roi Through Adoption Of Rfid Technology
    • Beyond The Pilot Projects
    • Case Study: Purdue Pharma Introduces Rfid Technology For Oxycontin
  • Chapter 4 Cooperation With National & International Agencies
    • Summary
    • Introduction
    • Improved Legislation
    • International Legislation
    • Who
    • Unicef
    • Interpol
    • Us Legislation
    • Domestic Drug Distribution
    • Internet Pharmacies
    • Drug Importation
    • European Legislation
    • Parallel Importation
    • Online Pharmacies
    • Legislation In Developing Countries
    • India
    • China
    • Case Study: Pfizer Partnership With Shanghai Municipal Food And Drug
    • Administration
    • Opinion On Government/Regulatory Agency Response
    • Industry Organizations
    • Psi
    • Ifpma
  • Appendix
    • Primary Research
    • References
    • Index
  • List Of Figures
    • Figure 1.1: Breakdown Of Type Of Counterfeit Drug, 2000-01
    • Figure 1.2: Estimates Of The Scale Of Drug Counterfeiting, 2005
    • Figure 1.3: Susceptibility Of Developed Countries To Drug Counterfeiting
    • Figure 1.4: Increase In Counterfeit Drug Cases, Us, 1997-2003
    • Figure 1.5: Opinions On The Changing Level Of Counterfeiting, 2000-2010
    • Figure 1.6: Most Common Types Of Drugs Counterfeited In Industrialized And Developing Countries
    • Figure 1.7: Drivers And Enablers Of Counterfeiting
    • Figure 1.8: Traditional Drug Distribution Channels, Us
    • Figure 1.9: Generalized Distribution Chain For Parallel Traded Pharmaceuticals In Europe
    • Figure 1.10: Top 15 Drugs Named Explicitly In Spam Email, February 2005
    • Figure 1.11: Countries Hosting Drug Spammer Websites, January 2005
    • Figure 1.12: Anti-Counterfeiting Strategies For Pharmaceutical Companies
    • Figure 2.13: How Are Pharmaceutical Companies Organized To Deal With The Counterfeiting Threat?, 2005
    • Figure 2.14: Typical Pharmaceutical Anti-Counterfeiting Team Structure
    • Figure 3.15: Cost Analysis Of Authentication Technologies
    • Figure 3.16: Frequency Of Use Of Anti-Counterfeiting Measures, 2005
    • Figure 3.17: How The Epc Works
    • Figure 3.18: Frequency Of Use Of Anti-Counterfeiting Measures, 2005
    • Figure 4.19: The Most Effective Measures To Combat Counterfeiting, 2005-2010
    • Figure 4.20: Proportion Of 191 Who Members With Adequate Drug Regulation, 2004
    • Figure 4.21: Organization Of Drug Regulatory Authorities In China, 2005
    • Figure 4.22: Has The Response Of Government And Regulatory Agencies In The Us, Eu, And Developing Countries Been Adequate?
    • Figure 4.23: Survey Respondents Split By Company Type
  • List Of Tables
    • Table 1.1: Defining Counterfeit Drugs
    • Table 1.2: National Specified List Of Susceptible Products, 2004
    • Table 2.3: Lawsuits Against Online Pharmacies Selling Illegal Viagra, 2004
    • Table 3.4: Benefits, Costs And Unresolved Issues With Rfid, 2004
    • Table 3.5: Example Of Real-Life Brand Protection Program Using Security Labels (Company Name Withheld)
    • Table 4.6: Share Of Parallel Imports In Total Pharmaceutical Sales, 2001